Page 63 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 3 Genomic Approaches to Hematology 35

signatures are based on relative transcript abundance (as opposed to, Cheung HW, Cowley GS, Weir BA, et al: Systematic investigation of genetic
for example, genome sequencing), it is subject to technical variation vulnerabilities across cancer cell lines reveals lineage-specific dependencies
such as stromal admixture of tumors that can distort a diagnostic in ovarian cancer. Proc Natl Acad Sci USA 108:12372, 2011.
signature. Third, although the academic publishing system tends to Cong L, Ran FA, Cox D, et al: Multiplex genome engineering using CRISPR/
reward initial discoveries (which are often published in high-profile Cas systems. Science 339:819–823, 2013.
journals), the essential follow-up validation studies tend to be valued Dryja TP, Cavenee W, White R, et al: Homozygosity of chromosome 13 in
less, and therefore investigators do not have an incentive to follow up retinoblastoma. N Engl J Med 310:550, 1984.
on their initial observations. Fourth, the economics of molecular Du J, Bernansconi P, Clauser KR, et al: Bead-based profiling of tyrosine
diagnostics have in general not been favorable, thus discouraging kinase phosphorylation identifies SRC as a potential target for glioblas-
companies from making major investments in the validation and toma therapy. Nat Biotechnol 27:77, 2009.
commercialization of promising diagnostic tests. It is likely that Emmert-Buck MR, Bonner RF, Smith PD, et al: Laser capture microdissec-
diagnostic tests will command more of a premium in the future as a tion. Science 274:998, 1996.
mechanism to use expensive therapeutics only in patients likely to Garraway LA, Lander ES: Lessons from the cancer genome. Cell 153:17,
benefit, but the time required for this to evolve is uncertain. 2013.
However, the potential utility of clinically relevant gene expression Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell
signatures has regained interest with the progress and greater avail- 144:646, 2011.
ability of sophisticated RNA sequencing technology. Whether RNA Hoshida Y, Villanueva A, Kobayashi M, et al: Gene expression in fixed tissues
sequencing provides data sufficiently robust to be used in clinical and outcome in hepatocellular carcinoma. N Engl J Med 359:1995, 2008.
routine remains to be established. Jaiswal S, Fontanillas P, Flannick J, et al: Age-related clonal hematopoiesis
associated with adverse outcomes. N Engl J Med 371:2488, 2014.
Jinek M, Chylinski K, Fonfara I, et al: A programmable dual-RNA-guided
FUTURE DIRECTIONS DNA endonuclease in adaptive bacterial immunity. Science 337:816–821,
2012.
The field of genomics has matured greatly over the past decade. Major Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF
analytical advances have made it possible to analyze and interpret inhibition through MAP kinase pathway reactivation. Nature 468:968,
complex datasets beyond what was previously possible. In addition, 2010.
dropping costs have made it possible to generate data at a scale that Lohr JG, Kim S, Gould J, et al: Genetic interrogation of circulating
was never before imaginable. DNA sequencing is now routine at multiple myeloma cells at single-cell resolution. Sci Transl Med 8:363ra147,
many academic centers and is increasingly being used to drive preci- 2016.
sion medicine by suggesting potential therapies based on individual Lohr JG, Adalsteinsson VA, Cibulskis K, et al: Whole-exome sequencing of
patients’ genetic profiles. Nevertheless, such approaches are still in circulating tumor cells provides a window into metastatic prostate cancer.
their infancy; the majority of patients do not receive direct benefit Nat Biotechnol 32:479, 2014.
from such precision medicine approaches. The future will also hold Macosko EZ, Basu A, Satija R, et al: Highly parallel genome-wide expression
an explosion of functional genomic studies, particularly using genome profiling of individual cells using nanoliter droplets. Cell 161:1202, 2015.
editing methods such as CRISPR/Cas9. With deep genomic, tran- Mardis ER, Ding L, Dooling DJ, et al: Recurring mutations found by
scriptomic, and epigenetic data already available for the most common sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058,
hematologic and malignant diseases, and with new data being gener- 2009.
ated at an ever-increasing rate, there will be great opportunity for Melo SA, Luecke LB, Kahlert C, et al: Glypican-1 identifies cancer exosomes
diagnostic and therapeutic development. The integration of genomic and detects early pancreatic cancer. Nature 523:177, 2015.
and other high-throughput sequencing approaches into clinical Miyamoto DT, Zheng Y, Wittner BS, et al: RNA-Seq of single prostate CTCs
research and routine clinical care will continue to be one of the implicates noncanonical Wnt signaling in antiandrogen resistance. Science
greatest challenges and opportunities in medicine in the decade 349:1351, 2015.
ahead. Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of
histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298,
2011.
SUGGESTED READINGS Nik-Zainal S, van Loo P, Wedge DC, et al: The life history of 21 breast
cancers. Cell 149:994, 2012.
Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell Paiva B, Vidriales MB, Cerveró J, et al: Multiparameter flow cytometric
lymphoma identified by gene expression profiling. Nature 403:503, 2000. remission is the most relevant prognostic factor for multiple myeloma
Armstrong SA, Staunton JE, Silverman LB, et al: MLL translocations specify patients who undergo autologous stem cell transplantation. Blood
a distinct gene expression profile that distinguishes a unique leukemia. 112:4017, 2008.
Nat Genet 30:41, 2002. Paweletz CP, Charboneau L, Bichsel VE, et al: Reverse phase protein microar-
Bernstein BE, Kamal M, Lindblad-Toh K, et al: Genomic maps and com- rays which capture disease progression show activation of pro-survival
parative analysis of histone modifications in human and mouse. Cell pathways at the cancer invasion front. Oncogene 20:1981, 2001.
120:169, 2005. Ramsköld D, Luo S, Wang YC, et al: Full-length mRNA-Seq from single-cell
Beroukhim R, Getz G, Nghiemphu L, et al: Assessing the significance of levels of RNA and individual circulating tumor cells. Nat Biotechnol
chromosomal aberrations in cancer: methodology and application to 30:777, 2012.
glioma. Proc Natl Acad Sci USA 104:20007, 2007. Robinson JT, Thorvaldsdóttir H, Winckler W, et al: Integrative genomics
Boyd SD, Marshall EL, Merker JD, et al: Measurement and clinical viewer. Nat Biotechnol 29:24, 2011.
monitoring of human lymphocyte clonality by massively parallel VDJ Rowley JD: The critical role of chromosome translocations in human leuke-
pyrosequencing. Sci Transl Med 1:12ra23, 2009. mias. Annu Rev Genet 32:495, 1998.
Buenrostro JD, Giresi PG, Zaba LC, et al: Transposition of native chro- Satija R, Farrell JA, Gennert D, et al: Spatial reconstruction of single-cell gene
matin for fast and sensitive epigenomic profiling of open chromatin, expression data. Nat Biotech 33:495–502, 2015.
DNA-binding proteins and nucleosome position. Nat Methods 10:1213, Schwarzenbach H, Hoon DSB, Pantel K: Cell-free nucleic acids as biomark-
2013. ers in cancer patients. Nat Rev Cancer 11:426, 2011.
Cabili MN, Trapnell C, Goff L, et al: Integrative annotation of human Shaffer AL, Emre NC, Lamy L, et al: IRF4 addiction in multiple myeloma.
large intergenic noncoding RNAs reveals global properties and specific Nature 454:226, 2008.
subclasses. Genes Dev 25:1915, 2011. Shipp MA, Ross KN, Tamayo P, et al: Diffuse large B-cell lymphoma outcome
Carter SL, Cibulskis K, Helman E, et al: Absolute quantification of somatic prediction by gene-expression profiling and supervised machine learning.
DNA alterations in human cancer. Nat Biotechnol 30:413, 2012. Nat Med 8:68, 2002.